Alnylam Pharmaceuticals revenue and financials

ALNY · NASDAQ · USD

$223.94+1.84%+$4.05

Close · October 6, 2026

In the fiscal year ended December 2025, Alnylam Pharmaceuticals reported revenue of $3.71B (+65.19% year over year). Net income was $313.75M, a net margin of 8.4%.

Annual revenue · 2025: $3.71B
  1. $89.91M2017
  2. $2.9M2017
  3. $74.91M2018
  4. $219.75M2019
  5. $492.85M2020
  6. $844.29M2021
  7. $1.04B2022
  8. $1.83B2023
  9. $2.25B2024
  10. $3.71B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+65.19%
2025 vs 2024
Net margin
8.4%
2024: -12.4%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1,2911,1671,0971,249774594593501660494440751
Cost of revenue29821126820014371.010385.968.766.085.984.3
Gross profit9929568291,049631523490415591428354666
Selling, general and administrative348323325322323240295221248211198199
Research and development413365372359324265300271294261272253
Operating income231269132368-16.218.1-105-76.948.6-43.4-116214
EBIT231269132368-16.218.1-105-76.948.6-43.4-116214
EBITDA245282145382-2.332.5-91.0-62.963.6-29.9-103227
Interest expense82.169.312944.461.558.339.034.433.335.331.330.9
Pre-tax income178222161239-41.3-2.4-194-109-11.2-63.6-138151
Income tax13.315.7-25.3-12.130.915.9-1102.95.72.30.23.0
Net income164206186251-72.2-18.3-83.8-112-16.9-65.9-138148
Net income to common shareholders164206186251-72.2-18.3-83.8-112-16.9-65.9-138148
Basic EPS1.231.551.411.91-0.55-0.14-0.65-0.87-0.13-0.52-1.101.18
Diluted EPS1.211.511.371.84-0.55-0.14-0.65-0.87-0.13-0.52-1.101.15
Average shares (basic)134133132131131130129129127126126125
Average shares (diluted)138138136137131130129129127126126131